Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)
| Autor: | Bodo Niggemann, Radvan Urbanek, S. Dreborg, Christian Möller, S. Halken, A Høst, A. Koivikko, Lars Jacobsen, Erkka Valovirta, Hosne Ara Ferdousi, Dieter Y. Koller, L A Norberg, Ulrich Wahn |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Budesonide
Allergy medicine.medical_specialty Adolescent Immunology Poaceae medicine.disease_cause Bronchial Provocation Tests Allergen Internal medicine medicine Humans Immunology and Allergy Child Betula Methacholine Chloride Conjunctivitis Allergic Asthma business.industry Rhinitis Allergic Seasonal Aeroallergen medicine.disease respiratory tract diseases Desensitization Immunologic Bronchial hyperresponsiveness Pollen Hay fever Methacholine Seasons business medicine.drug |
| Zdroj: | Möller, C, Dreborg, S, Ferdousi, H A, Halken, S, Høst, A, Jacobsen, L, Koivikko, A, Koller, D Y, Niggemann, B, Norberg, L A, Urbanek, R, Valovirta, E & Wahn, U 2002, ' Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study) ', Journal of Allergy and Clinical Immunology, vol. 109, no. 2, pp. 251-256 . https://doi.org/10.1067/mai.2002.121317 |
| ISSN: | 0091-6749 |
| Popis: | BACKGROUND: Children with allergic rhinitis are likely to develop asthma.OBJECTIVE: The purpose of this investigation was to determine whether specific immunotherapy can prevent the development of asthma and reduce bronchial hyperresponsiveness in children with seasonal allergic rhinoconjunctivitis.METHODS: From 6 pediatric allergy centers, 205 children aged 6 to 14 years (mean age, 10.7 years) with grass and/or birch pollen allergy but without any other clinically important allergy were randomized either to receive specific immunotherapy for 3 years or to an open control group. All subjects had moderate to severe hay fever symptoms, but at inclusion none reported asthma with need of daily treatment. Symptomatic treatment was limited to loratadine, levocabastine, sodium cromoglycate, and nasal budesonide. Asthma was evaluated clinically and by peak flow. Methacholine bronchial provocation tests were carried out during the season(s) and during the winter.RESULTS: Before the start of immunotherapy, 20% of the children had mild asthma symptoms during the pollen season(s). Among those without asthma, the actively treated children had significantly fewer asthma symptoms after 3 years as evaluated by clinical diagnosis (odds ratio, 2.52; P CONCLUSION: Immunotherapy can reduce the development of asthma in children with seasonal rhinoconjunctivitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect